As of November 10, 2026, Immunovant, Inc. is a publicly traded company (Nasdaq: IMVT). Roivant Sciences Ltd. reports holding 55.9%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (8.4%) (Schedule 13D/A, December 12, 2025).
Is this your company?
About to sign with, pay or invest in Immunovant, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Immunovant, Inc. a real, registered company?
- Immunovant, Inc. files with the SEC under CIK 1764013 (its SEC filings).
- Its shares are listed under the ticker IMVT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Durham, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Immunovant, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Roivant Sciences Ltd. (filed 2025-12-12).
Who are Immunovant, Inc.'s owners and officers?
Immunovant, Inc.: incorporated in Delaware; business address in Durham, North Carolina; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-01-21)
- : Executive Officer (Form D, 2025-01-21)
- : Executive Officer (Form D, 2025-01-21)
- : Executive Officer (Form D, 2025-01-21)
- : Executive Officer (Form D, 2025-01-21)
- : Executive Officer (Form D, 2025-01-21)
- : Executive Officer (Form D, 2025-01-21)
- : Director (Form D, 2025-01-21)
- : Director (Form D, 2025-01-21)
- : Director (Form D, 2025-01-21)
- : Director (Form D, 2025-01-21)
- : Director (Form D, 2025-01-21)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 4.55% |
| Schedule 13D/A, 2025-12-12 | Roivant Sciences LTD. | 55.9% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 8.4% |
Questions about who owns Immunovant, Inc.
Who owns Immunovant, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Immunovant, Inc.: Roivant Sciences LTD. (55.9%, Schedule 13D/A, filed 2025-12-12) and Fmr LLC (8.4%, Schedule 13G/A, filed 2025-11-05).
Who are the largest shareholders of Immunovant, Inc.?
By the share each holder's latest filing reports, the largest holders of Immunovant, Inc. on this page are Roivant Sciences LTD. (55.9%) and Fmr LLC (8.4%).
When did Roivant Sciences LTD. buy into Immunovant, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Roivant Sciences LTD. on this page is the Schedule 13D/A, filed 2025-12-12, reporting 55.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Immunovant, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Immunovant, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunovant, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Immunovant, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Roivant Sciences Ltd., a director and 10% owner: 113,317,007 shares (54.8% of shares outstanding) (Form 4, 2025-12-12).
- , the chief executive and a director: 1,178,191 shares (0.57% of shares outstanding) (Form 4, 2025-04-17).
- , a director: 1,009,228 shares (0.49% of shares outstanding) (Form 4, 2026-04-09).
- , the chief financial officer: 396,774 shares (0.19% of shares outstanding) (Form 4, 2025-04-17).
- , the chief medical officer: 357,353 shares (0.17% of shares outstanding) (Form 4, 2025-02-21).
Shares outstanding: 206,947,758 as of 2026-11-03, from the company's latest SEC cover page.
How much has Immunovant, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-01-21 | $450M | $450M |
Keep reading
More on Immunovant, Inc. and the records around it.
Immunovant, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Roivant Sciences Ltd. also filed stake reports on 1 other company: Arbutus Biopharma Corp (Oct 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/immunovant